Adagrasib

Adagrasib

Adagrasib (MRTX849) is a potent, orally available, and mutation-selective covalent KRAS G12C inhibitor. It binds irreversibly to cysteine 12, locking KRAS in its inactive GDP-bound state and blocking KRAS-dependent signaling for potential antitumor activity. Reagent grade, for research use only.

Molecular structure of the compound BP-43624
    • Unit
    • Price
    • Qty
    • 100 MG
    • $130.00
    • 250 MG
    • $250.00
    • 500 MG
    • $450.00
    • 1 G
    • $750.00

Usually ships within 24 hours.

Would you like to inquire about custom quantity?
Inquire